Post Translational Medicines

Building the world’s first Aging Atlas

Based based in San Francisco Ca United States, Post Translational Medicines works in biopharma, founded in 2025.

Profile

Post Translational Medicines (PTM) is pioneering a new paradigm in drug discovery by systematically targeting the dynamic regulatory layer of biology that exists beyond the genome and proteome: the Dark Proteome. Rather than focusing solely on protein abundance or genetic mutation, PTM is building an in cellulo proteome-wide “motion tracking” platform that maps, interprets, and therapeutically modulates proteoforms at scale. By integrating advanced proteomics, computational modeling, and small molecule discovery, PTM aims to unlock a vast and largely untapped space of druggable biology—enabling the development of first-in-class therapies for age-related and chronic diseases.

As a business in biopharma, Post Translational Medicines is listed here with the public details available about it.

The company is recorded as being based in San Francisco Ca United States.

The company is listed at the SOSV portfolio company stage of development.

Its team size is recorded as 2-10 employees.

Total disclosed funding stands at about $5K.

Website: ptmedicines.com